Outset Medical Inc
$ 4.49
4.42%
12 Jun - close price
- Market Cap 83,232,000 USD
- Current Price $ 4.49
- High / Low $ 4.62 / 4.20
- Stock P/E N/A
- Book Value 6.03
- EPS -2.74
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.53 %
- 52 Week High 21.36
- 52 Week Low 3.00
About
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. The company is headquartered in San Jose, California.
Analyst Target Price
$8.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-11 | 2025-11-10 | 2025-08-06 | 2025-05-07 | 2025-02-19 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-21 | 2023-11-07 | 2023-08-02 |
| Reported EPS | -0.83 | -0.84 | -0.69 | -0.84 | -3.24 | -5.55 | -5.85 | -7.05 | -8.55 | -8.85 | -10.65 | -10.35 |
| Estimated EPS | -0.79 | -0.67 | -0.65 | -0.98 | -0.94 | -6.19 | -6.32 | -6.79 | -8.23 | -9.22 | -10 | -10.89 |
| Surprise | -0.04 | -0.17 | -0.04 | 0.14 | -2.3 | 0.64 | 0.47 | -0.26 | -0.32 | 0.37 | -0.65 | 0.54 |
| Surprise Percentage | -5.0633% | -25.3731% | -6.1538% | 14.2857% | -244.6809% | 10.3393% | 7.4367% | -3.8292% | -3.8882% | 4.013% | -6.5% | 4.9587% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.88 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OM
2026-06-08 11:10:39
Outset Medical's Chief Financial Officer, Renee Gaeta, recently sold US$87k worth of company stock, reducing her holding by 13%. This sale, at roughly the current share price of US$4.58, was the largest insider sale in the past year, with no insider purchases reported during the same period. Insiders hold 2.8% of the company, and the article suggests careful consideration before investing due to the selling activity and relatively low insider ownership.
2026-06-06 06:10:04
Outset Medical director Kevin C. O’Boyle received an equity award of 10,667 restricted stock units (RSUs) as compensation, not a market purchase. These RSUs will vest 100% on the earlier of one year from the grant date or the company's next Annual Meeting of Stockholders. Following this award, O’Boyle directly holds 34,785 shares of Outset Medical common stock.
2026-06-06 05:40:14
Outset Medical director Karen Prange has been granted 10,667 restricted stock units (RSUs), increasing her direct holdings to 29,334 shares. These RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. This equity award is compensation-related and not an open-market purchase.
2026-06-05 23:10:03
Outset Medical director Patrick T. Hackett was granted 10,667 shares of common stock as a stock award, vesting 100% on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following this grant, Hackett directly holds 105,839 shares and indirectly owns 41,666 shares through the Hackett Family Fund and 83,333 shares through the GST Trust. The transaction was a compensation-related acquisition and not a market trade.
2026-06-05 22:10:02
Outset Medical, Inc. director Brent D. Lang was granted 10,667 shares of Common Stock as a stock award with a stated price of $0.0000 per share, representing restricted stock units. These RSUs will fully vest upon the earlier of one year from the grant date or the company's next Annual Meeting of Stockholders. Following this transaction, Lang directly holds 28,518 shares and indirectly holds 16,666 shares through the Lang Family Trust.
2026-06-05 22:10:02
Outset Medical (OM) director D. Keith Grossman received an equity award of 10,667 shares of common stock, granted at $0.00 per share. These shares are RSUs that will vest either one year from the grant date or by the company's next Annual Meeting of Stockholders. Following this grant, Grossman directly holds 24,585 shares and indirectly holds 12,845 shares through the Grossman Fam Trust.
